Recent Finacing
Recent Raise
Janux is a preclinical biotech developing tumor-activated bispecific T cell engagers (TRACTr) with modular design to improve pharmacokinetics and limit systemic immune activation, targeting PSMA, EGFR, and TROP2.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Janux Therapeutics.
